Showing results (41-50 of 98) with videos related to
Sort By:
Pageof 10
Journal of Hematotherapy & Stem Cell Research|September 11, 2003
Involvement of cyclin D1 and E2F1 in intramedullary apoptosis in myelodysplastic syndromesGurveen Saberwal, Eileen Broderick, Imke Janssen, et al.Leukemia Research|November 12, 2010
Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromesRong Wang, Cary P Gross, Ronald J Maggiore, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2008
Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromesMikkael A Sekeres, Jaroslaw P Maciejewski, Aristotle A N Giagounidis, et al.Haematologica|November 13, 2008
Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveatsSa A Wang, Olga Pozdnyakova, Jeffrey L Jorgensen, et al.Leukemia Research|September 25, 2007
Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcomeGang Yue, Suyang Hao, Oluwole Fadare, et al.Leukemia Research|August 25, 2012
The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromesRong Wang, Cary P Gross, Kevin Frick, et al.Molecular Cell|September 3, 2019
Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1Jian Zhang, Abdullah M Ali, Yen K Lieu, et al.Plos One|October 7, 2014
A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemiaAaron D Schimmer, Azra Raza, Thomas H Carter, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndromeAlan F List, Maria R Baer, David P Steensma, et al.Blood|February 1, 2007
A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndromePierre Fenaux, Azra Raza, Ghulam J Mufti, et al.Pageof 10